logo dark logoo light logo
  • Home
  • About Us
  • News
  • Contact
mobile logo
  • Home
  • About Us
  • News
  • Contact

BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS

January 18, 2021
in Sin categoría
by bio_info_gate@admin

OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest....

Continue reading

NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X

October 15, 2020
in news
by bio_info_gate@admin

Bioinfogate will integrate JADER case reports and pharmacovigilance signals into OFF-X to complement its unique translational view of safety intelligence....

Continue reading

LAUNCH OF BIOINFOGATE’S OFF-X TRANSLATABILITY DASHBOARD

July 23, 2020
in news
by bio_info_gate@admin

The Translatability Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic...

Continue reading

FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL

May 26, 2020
in Sin categoría
by bio_info_gate@admin

The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health. ...

Continue reading

BIOINFOGATE’S OFF-X PROVIDES A DEDICATED “COVID-19” SECTION

April 2, 2020
in Sin categoría
by bio_info_gate@admin

The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care. ...

Continue reading

BIOINFOGATE’S OFF-X REACHES HALF MILLION SAFETY ALERTS

January 13, 2020
in Sin categoría
by bio_info_gate@admin

Launched in 2017, OFF-X has now reached 500,000 curated safety alerts corresponding to almost 15,000 targets of pharmacological interest and almost 14,500 drugs and biologics. ...

Continue reading

BIOINFOGATE SUCCESSFULLY COMPLETES NEOTEC PROJECT SUPPORTED BY CDTI (CENTER FOR THE DEVELOPMENT OF INDUSTRIAL TECHNOLOGY)

December 31, 2019
in news
by bio_info_gate@admin

Bioinfogate is pleased to announce successful completion of the R&D innovation project "DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE PLATFORM TO ANTICIPATE AND MINIMIZE THE RISKS ASSOCIATED WITH THE SAFETY OF DRUGS FROM THEIR PHASE OF DISCOVERY THROUGH THEIR USE IN CLINICAL PRACTICE"....

Continue reading

BIOINFOGATE TO PRESENT AT THE CHEM-BIO INFORMATICS SOCIETY (CBI) ANNUAL MEETING (TOKYO, JAPAN, OCTOBER 22-24, 2019)

October 10, 2019
in Sin categoría
by bio_info_gate@admin

Bioinfogate has been invited to a speak at the Chem-Bio Informatics Society (CBI) Annual Meeting ""Towards Seamless Integration of Structural Biology and Information Science"~Dawn of the AI era in drug discovery~" which takes place in Tokyo, Oct. 22-24, 2019. ...

Continue reading

BIOINFOGATE EXHIBITING AT THE SAFETY PHARMACOLOGY SOCIETY ANNUAL MEETING IN BARCELONA (SEPTEMBER 23-25, 2019)

September 20, 2019
in Sin categoría
by bio_info_gate@admin

Bioinfogate will be showcasing some of their recent developments at the Safety Pharmacology Society Annual Meeting in Barcelona, September 23-26, 2019....

Continue reading

RESEARCH INSTITUTES OF SWEDEN (RISE) INITIATES SUBSCRIPTION TO BIOINFOGATE OFF-X

June 20, 2019
in Sin categoría
by bio_info_gate@admin

RISE selected OFF-X to support the work of researchers in drug R&D to perform target safety assessment for early projects. ...

Continue reading

VHIO AND BIOINFOGATE PARTNER TO ENHANCE SAFETY ASSESSMENT IN CLINICAL RESEARCH

June 17, 2019
in Sin categoría
by bio_info_gate@admin

Announced today, the Vall d´Hebron Institute of Oncology - Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies. ...

Continue reading

BIOINFOGATE EXHIBITING AT WORLD PHARMA WEEK IN BOSTON, MA (JUNE 17-20, 2019)

June 14, 2019
in Sin categoría
by bio_info_gate@admin

Bioinfogate will be showcasing some of their recent developments at booth 133....

Continue reading

FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO ACCESS THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL

May 21, 2019
in Sin categoría
by bio_info_gate@admin

Under this MTA, the FDA has agency-wide access to Bioinfogate’s translational safety intelligence portal, OFF-X. ...

Continue reading

NEW ALLIANCE BETWEEN CLARIVATE ANALYTICS AND BIOINFOGATE TO DELIVER SAFETY & TOXICITY INTELLIGENCE TO PHARMA AND HEALTHCARE RESEARCHERS AND DECISION MAKERS

March 4, 2019
in Sin categoría
by bio_info_gate@admin

Bioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest....

Continue reading

BIOINFOGATE EXHIBITING AT THE SOCIETY OF TOXICOLOGY’S 58TH ANNUAL MEETING AND TOXEXPO IN BALTIMORE, MD (MARCH 10-14, 2019)

February 15, 2019
in Sin categoría
by bio_info_gate@admin

Bioinfogate will be showcasing some of their recent developments....

Continue reading

Recent Post

  • BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS
  • NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X
  • LAUNCH OF BIOINFOGATE’S OFF-X TRANSLATABILITY DASHBOARD
  • FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
  • BIOINFOGATE’S OFF-X PROVIDES A DEDICATED “COVID-19” SECTION

Archives

  • January 2021
  • October 2020
  • July 2020
  • May 2020
  • April 2020
  • January 2020
  • December 2019
  • October 2019
  • September 2019
  • June 2019
  • May 2019
  • March 2019
  • February 2019

About Us

BioInfoGate is a forward thinking, private company working to solve unmet medical needs. BioInfoGate helps companies, academic institutions, and government and regulatory agencies working in scientific research and drug R&D. Our innovative knowledge management tools and analytics software solutions support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and identifying and investing in emerging projects that align with our core business in life sciences and data analytics.

Our passion and capabilities stem from more than 50 years’ experience creating and managing biomedical knowledge, first at Prous Science (acquired by Thomson Reuters in 2007), and then at the Prous Institute for Biomedical Research. BioInfoGate is the next generation firm within the Prous family of companies, embracing a long tradition and expertise in scientific knowledge management.

Company

  • About Us
  • Contact
  • News
  • Copyright and Legal Notice
  • Privacy policy
  • Cookie policy
© 2021 All Right Reserved
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.